Literature DB >> 1618546

Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide.

F J Salazar1, J M Pinilla, F López, J C Romero, T Quesada.   

Abstract

The aim of the present study was to investigate in conscious dogs the long-term effects of nitric oxide synthesis inhibition on glomerular filtration rate, sodium and water excretion, and plasma levels of renin and aldosterone. After a control period of 3 days, an inhibitor of endothelium-derived nitric oxide synthesis, NG-nitro-L-arginine-methyl ester, was infused for 3 consecutive days at a dose (50 ng/kg/min) that did not induce significant changes in arterial pressure (n = 6). The inhibition of nitric oxide synthesis led to a large and sustained decrease (p less than 0.05) in glomerular filtration rate of approximately 35%. This change was accompanied by a decrease (p less than 0.05) in urinary sodium excretion from 78.9 +/- 4.6 meq/day to 49.8 +/- 6.8, 60.1 +/- 4.2, and 53.5 +/- 9.0 meq/day by days 1, 2, and 3 of nitric oxide synthesis inhibition, respectively. Changes in fractional sodium excretion failed to achieve statistical significance. Nitric oxide synthesis inhibition also induced a significant and sustained decrease in urine flow rate. The decrease in glomerular filtration rate, natriuresis, and diuresis was accompanied by a 45% increase in plasma renin activity (p less than 0.05) and no change in plasma aldosterone concentration. By day 3 of the recovery period, glomerular filtration rate, natriuresis, diuresis, and plasma renin activity returned to values similar to those found during the control period. The administration of L-arginine during 3 consecutive days (5 micrograms/kg.min i.v.) did not modify any of the parameters measured but effectively prevented all the renal changes induced by the 3 days of nitric oxide synthesis inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618546     DOI: 10.1161/01.hyp.20.1.113

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  19 in total

1.  Role of endothelin-1 in the hyper-responsiveness to nitrovasodilators following acute NOS inhibition.

Authors:  Stephane L Bourque; Heather A Whittingham; Susan E Brien; Sandra T Davidge; Michael A Adams
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Decreased renal haemodynamic response to inhibition of nitric oxide synthase in subtotally nephrectomized rats.

Authors:  J Wagner; A Wystrychowski; H Stauss; D Ganten; E Ritz
Journal:  Pflugers Arch       Date:  1995-06       Impact factor: 3.657

Review 3.  Chronic nitric oxide inhibition model six years on.

Authors:  R Zatz; C Baylis
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

4.  Role of prostanoids and nitric oxide inhibition in rats with experimental hepatic fibrosis.

Authors:  M Criado; O Flores; M J Vázquez; A Esteller
Journal:  J Physiol Biochem       Date:  2000-09       Impact factor: 4.158

5.  Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Authors:  M Hropot; K H Langer; Gabriele Wiemer; H Grötsch; W Linz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

6.  Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model.

Authors:  P Soares-da-Silva; M Pestana; M A Vieira-Coelho; M H Fernandes; A Albino-Teixeira
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 7.  Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension.

Authors:  Agustin Gonzalez-Vicente; Fara Saez; Casandra M Monzon; Jessica Asirwatham; Jeffrey L Garvin
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

8.  Inhibition of endothelial derived relaxing factor (EDRF) aggravates ischemic acute renal failure in anesthetized rats.

Authors:  M S Chintala; P J Chiu; S Vemulapalli; R W Watkins; E J Sybertz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

9.  FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats.

Authors:  Yohannes T Ghebremariam; Keisuke Yamada; Jerry C Lee; Christine L C Johnson; Dorothee Atzler; Maike Anderssohn; Rani Agrawal; John P Higgins; Andrew J Patterson; Rainer H Böger; John P Cooke
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

10.  Eicosanoid-dependence of responses of pre- but not postglomerular vessels to noradrenaline in rat isolated kidneys.

Authors:  B L Zhang; J Sassard
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.